BR0006403A - Composição de dosagem oral de liberação prolongada estável - Google Patents

Composição de dosagem oral de liberação prolongada estável

Info

Publication number
BR0006403A
BR0006403A BR0006403-3A BR0006403A BR0006403A BR 0006403 A BR0006403 A BR 0006403A BR 0006403 A BR0006403 A BR 0006403A BR 0006403 A BR0006403 A BR 0006403A
Authority
BR
Brazil
Prior art keywords
hours
oral dosage
composition
release oral
dosage composition
Prior art date
Application number
BR0006403-3A
Other languages
English (en)
Inventor
Jim H Kou
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22629437&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0006403(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of BR0006403A publication Critical patent/BR0006403A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Toys (AREA)
  • Cosmetics (AREA)

Abstract

Patente de Invenção: <B>"COMPOSIçãO DE DOSAGEM ORAL DE LIBERAçãO PROLONGADA ESTáVEL"<D>. Uma composição de dosagem oral sólida de liberação prolongada e revestida por filme contendo um descongestionante nasal, pseudoefe-drina ou um sal seu, por exemplo o sulfato de pseudoefedrina, em um núcleo efetivo para fornecer uma concentração de pseudoefedrina plasmática máxima geométrica de cerca de 345 ng/ml a cerca de 365 ng/ml em um tempo de cerca de 7,60 horas a cerca de 8,40 horas e apresentando dois ou três revestimentos de filme no núcleo, com o segundo contendo uma quantidade da anti-histamina não sedativa, desloratadina, efetiva para fornecer uma concentração de desloratadina plasmática máxima geométrica de cerca de 2,15 ng/ml a cerca de 2,45 ng/ml em um tempo de cerca de 4,0 horas a cerca de 4,5 horas e o uso da composição para o tratamento de pacientes que apresentam sinais e sintomas associados com condições alérgicas e/ou inflamatórias da pele e das passagens das vias aéreas são revelados.
BR0006403-3A 1999-12-20 2000-12-20 Composição de dosagem oral de liberação prolongada estável BR0006403A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17283699P 1999-12-20 1999-12-20

Publications (1)

Publication Number Publication Date
BR0006403A true BR0006403A (pt) 2001-07-17

Family

ID=22629437

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0006403-3A BR0006403A (pt) 1999-12-20 2000-12-20 Composição de dosagem oral de liberação prolongada estável

Country Status (38)

Country Link
US (2) US6979463B2 (pt)
EP (2) EP2196195A3 (pt)
JP (3) JP5042403B2 (pt)
KR (2) KR100936572B1 (pt)
CN (3) CN1211079C (pt)
AR (1) AR027033A1 (pt)
AT (1) ATE463240T1 (pt)
AU (4) AU2277101A (pt)
BR (1) BR0006403A (pt)
CA (1) CA2329217C (pt)
CO (1) CO5251435A1 (pt)
CY (1) CY1110693T1 (pt)
CZ (1) CZ302860B6 (pt)
DE (1) DE60044117D1 (pt)
DK (1) DK1112738T3 (pt)
EC (1) ECSP003836A (pt)
EG (1) EG23759A (pt)
ES (1) ES2341751T3 (pt)
HK (1) HK1034453A1 (pt)
HU (1) HUP0004988A3 (pt)
ID (1) ID28675A (pt)
IL (1) IL140450A (pt)
MX (1) MXPA00013037A (pt)
MY (1) MY130773A (pt)
NO (1) NO331645B1 (pt)
NZ (1) NZ509028A (pt)
PE (1) PE20010982A1 (pt)
PL (1) PL211573B1 (pt)
PT (1) PT1112738E (pt)
RU (2) RU2303440C2 (pt)
SA (2) SA01210741B1 (pt)
SG (1) SG109438A1 (pt)
SI (1) SI1112738T1 (pt)
SK (1) SK287684B6 (pt)
TR (1) TR200003787A2 (pt)
TW (1) TWI225414B (pt)
WO (1) WO2001045668A2 (pt)
ZA (1) ZA200007715B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045668A2 (en) 1999-12-20 2001-06-28 Schering Corporation Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine
AU2276801A (en) 1999-12-20 2001-07-03 Schering Corporation Extended release oral dosage composition
US7405223B2 (en) 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
JP2004534820A (ja) * 2001-06-20 2004-11-18 シェーリング　コーポレイション 鼻うっ血および鼻閉塞の処置のための抗ヒスタミン薬
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
SI1476138T1 (sl) 2002-02-21 2012-07-31 Valeant Internat Barbados Srl Formulacije s prirejenim sproščanjem vsaj ene oblike tramadola
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
WO2004108700A1 (en) * 2003-03-12 2004-12-16 Teva Gyogyszergyar Reszvenytarsasag Processes for preparation of polymorphic forms of desloratadine
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
WO2005053599A1 (ja) * 2003-12-01 2005-06-16 Takeda Pharmaceutical Company Limited 固形製剤の印刷前処理方法及び印刷前処理方法が施された固形製剤
US20060110449A1 (en) * 2004-10-25 2006-05-25 Lorber Richard R Pharmaceutical composition
US20060252831A1 (en) * 2005-05-06 2006-11-09 Christopher Offen Method for the treatment of magnesium and potassium deficiencies
US20060252830A1 (en) * 2005-05-06 2006-11-09 Brandon Stephen F Method for the treatment of magnesium and potassium deficiencies
US20070014855A1 (en) * 2005-07-12 2007-01-18 Rahul Gawande S Stable desloratadine compositions
US20070036859A1 (en) * 2005-08-11 2007-02-15 Perry Ronald L Sustained release antihistamine and decongestant composition
US8297028B2 (en) 2006-06-14 2012-10-30 The Invention Science Fund I, Llc Individualized pharmaceutical selection and packaging
US10296720B2 (en) 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
US7974856B2 (en) 2005-11-30 2011-07-05 The Invention Science Fund I, Llc Computational systems and methods related to nutraceuticals
US7827042B2 (en) 2005-11-30 2010-11-02 The Invention Science Fund I, Inc Methods and systems related to transmission of nutraceutical associated information
US20080210748A1 (en) 2005-11-30 2008-09-04 Searete Llc, A Limited Liability Corporation Of The State Of Delaware, Systems and methods for receiving pathogen related information and responding
US8340944B2 (en) 2005-11-30 2012-12-25 The Invention Science Fund I, Llc Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US8000981B2 (en) 2005-11-30 2011-08-16 The Invention Science Fund I, Llc Methods and systems related to receiving nutraceutical associated information
US7927787B2 (en) 2006-06-28 2011-04-19 The Invention Science Fund I, Llc Methods and systems for analysis of nutraceutical associated components
FR2894143B1 (fr) 2005-12-01 2008-05-02 Pierre Fabre Medicament Sa Composition a liberation prolongee de l'actif, son procede de preparation et son utilisation.
TW200808376A (en) * 2006-06-01 2008-02-16 Schering Corp Phenylephrine pulsed release formulations and pharmaceutical compositions
NZ573174A (en) * 2006-06-01 2012-01-12 Msd Consumer Care Inc Sustained release pharmaceutical dosage form containing phenylephrine
BRPI0712532A2 (pt) * 2006-06-01 2013-04-02 Schering Plough Healthcare Prod Inc formulaÇÕes e composiÇÕes farmacÊuticas de fenilefrina para absorÇço colânica
KR101464771B1 (ko) * 2006-06-01 2014-11-26 머크 샤프 앤드 돔 코포레이션 페닐에프린의 지속 방출용 약제학적 조성물
CA2658170A1 (en) * 2006-07-11 2008-01-17 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
BRPI0812784A2 (pt) * 2007-06-01 2014-12-02 Schering Plough Healthcare Composição farmacêutica compreendendo um substrato e um revestimento contendo um ingrediente ativo e polivinilálcool
PE20091084A1 (es) * 2007-12-07 2009-07-23 Schering Plough Healthcare Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal
EP3045043B1 (en) 2009-02-26 2020-04-29 Relmada Therapeutics, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
WO2010143202A1 (en) * 2009-06-09 2010-12-16 Sun Pharmaceutical Industries Ltd. Pharmaceutical composition
TR201009396A2 (tr) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Desloratadin granüller
DE102016107760B4 (de) * 2016-04-26 2018-09-20 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Essbare Funktionsschichten und Überzüge auf Hybridpolymerbasis für Pharmazie und Lebensmittel
US20180187263A1 (en) 2017-01-05 2018-07-05 Iowa State University Research Foundation, Inc. Kits for diagnostic detection and prevention of feedlot bovine respiratory disease
EP4188339A1 (en) 2020-07-30 2023-06-07 Faes Farma, S.A. Decongestant drug delivery system

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US100000A (en) 1870-02-22 Improved sun-bonnet for horses
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3940485A (en) 1973-12-12 1976-02-24 Levinson Harold N Treatment and pre-treatment of dysmetric dyslexia by improving sequential scanning and ocular fixation abilities and therapeutic compounds
US4008796A (en) 1974-03-26 1977-02-22 General Concrete Of Canada Limited Control method for feeding items on a conveyor
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US4282233B1 (en) 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
JPS61501205A (ja) 1984-02-15 1986-06-19 シェリング・コ−ポレ−ション ８↓−クロル↓−６，１１↓−ジヒドロ↓−１１↓−（４↓−ピペリジリデン）↓−５Ｈ↓−ベンゾ〔５，６〕シクロヘプタ〔１，２−ｂ〕ピリジンおよびその塩、これらの化合物の製造方法、ならびにこれらの化合物を含有する医薬組成物
US4783465A (en) 1984-04-09 1988-11-08 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US4552899A (en) 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
SE8404467D0 (sv) 1984-09-06 1984-09-06 Ferrosan Ab Controlled-release medical preparations
US4731447A (en) 1985-05-13 1988-03-15 Schering Corporation Process for preparing piperidylidene dihydro-dibenzo(a,d)-cycloheptenes or aza-derivatives thereof
US4804666A (en) 1985-08-14 1989-02-14 Schering Corporation Antiallergic 6,11-dihydro-11-(4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines
JPS6396126A (ja) 1986-10-13 1988-04-27 Taisho Pharmaceut Co Ltd 安定化組成物
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
US4777170A (en) 1987-02-03 1988-10-11 Heinrich William A Method to prevent and treat the signs and symptoms of motion sickness
GB8707421D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
US4863931A (en) * 1988-09-15 1989-09-05 Schering Corporation Antihistaminic fluoro substituted benzocycloheptapyridines
US5019591A (en) * 1989-02-17 1991-05-28 Pennsylvania Research Corporation Method for treating retinopathy and other small vessel disorders associated with diabetes
US4990535A (en) 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
IL98572A (en) 1990-06-22 1995-07-31 Schering Corp Bite-benzo or benzopyrido compounds Cyclohepta piperidine, piperidylidene and piperazine, preparations and methods of use.
CA2098198A1 (en) 1990-12-18 1992-06-18 Ann Christie King Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
MX9202350A (es) 1991-05-20 1992-11-01 Alza Corp Composiciones de incrementador de penetracion a la piel que usan monolinoleato de glicerol.
YU48263B (sh) 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
ES2042421B1 (es) * 1992-05-22 1994-08-01 Uriach & Cia Sa J Procedimiento para la obtencion de la 8-cloro-11-*1-*(5-metil-3-piridil)metil*-4-piperidiliden*-6,11-dihidro-5h-benzo*5,6*ciclohepta*1,2-b*piridina.
US5314697A (en) * 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
IT1264517B1 (it) 1993-05-31 1996-09-24 Ekita Investments Nv Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
JP2646972B2 (ja) 1993-11-01 1997-08-27 日本電気株式会社 多ビットメモリ
DE4442999A1 (de) 1994-12-02 1996-06-05 Hexal Pharma Gmbh Pharmazeutische Zusammensetzung mit einem aktiven Loratidin-Metaboliten
US5595997A (en) 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
US5807579A (en) * 1995-11-16 1998-09-15 F.H. Faulding & Co. Limited Pseudoephedrine combination pharmaceutical compositions
KR20000052922A (ko) * 1996-10-31 2000-08-25 둘락 노먼 씨. 로라타딘 및 충혈제거제를 함유하는 천식 치료용 조성물
PE71699A1 (es) * 1997-02-07 1999-08-03 Sepracor Inc Composicion farmaceutica de descarboetoxiloratadina sin lactosa, no higroscopica y anhidra
US5900421A (en) * 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
US5939426A (en) * 1997-02-28 1999-08-17 Sepracor Inc. Methods for treating urinary incontinence using descarboethoxyloratadine
US6506767B1 (en) * 1997-07-02 2003-01-14 Schering Corporation 8-chloro-6,11-dihydro-11-(4-piperidylidine)-5H-benzo[5,6]cyclohepta[1-2-b] pyridine
US6270796B1 (en) * 1997-10-29 2001-08-07 Robert E. Weinstein Antihistamine/decongestant regimens for treating rhinitis
US6132758A (en) * 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
AU741201B2 (en) 1998-07-10 2001-11-22 Merck Sharp & Dohme Corp. 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo(5,6) cyclohepta (1,2-b)pyridine oral compositions
US6423721B1 (en) 1998-09-10 2002-07-23 Schering Corporation Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
US6521254B2 (en) * 1998-12-07 2003-02-18 J-Med Pharmaceuticals, Inc. Single-dose antihistamine/decongestant formulations for treating rhinitis
US6051585A (en) * 1998-12-07 2000-04-18 Weinstein; Robert E. Single-dose antihistamine/decongestant formulations for treating rhinitis
US6100274A (en) 1999-07-07 2000-08-08 Schering Corporation 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
US6114346A (en) * 1999-10-22 2000-09-05 Schering Corporation Treating sleep disorders using desloratadine
WO2001045668A2 (en) 1999-12-20 2001-06-28 Schering Corporation Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine
AU2276801A (en) 1999-12-20 2001-07-03 Schering Corporation Extended release oral dosage composition
US7405223B2 (en) 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
CN1213752C (zh) 2000-02-03 2005-08-10 先灵公司 变应性和炎性疾病的治疗
CN1173697C (zh) 2000-05-19 2004-11-03 爱尔康公司 用于治疗过敏性疾病的苯胺二硫化物衍生物
US6599913B1 (en) 2001-06-29 2003-07-29 Schering Corporation Treating allergic and inflammatory conditions

Also Published As

Publication number Publication date
AU2277101A (en) 2001-07-03
NO20006504D0 (no) 2000-12-20
JP2012224642A (ja) 2012-11-15
CN1211079C (zh) 2005-07-20
TWI225414B (en) 2004-12-21
ZA200007715B (en) 2001-06-20
SA06270069B1 (ar) 2009-06-07
RU2423106C2 (ru) 2011-07-10
US20060159761A1 (en) 2006-07-20
EP1112738A2 (en) 2001-07-04
SA01210741A (ar) 2005-12-03
NO331645B1 (no) 2012-02-13
MXPA00013037A (es) 2003-06-19
DE60044117D1 (de) 2010-05-20
NO20006504L (no) 2001-06-21
JP5042403B2 (ja) 2012-10-03
SI1112738T1 (sl) 2010-07-30
JP2008081510A (ja) 2008-04-10
AU2009200460B2 (en) 2012-01-19
CY1110693T1 (el) 2015-06-10
CN1679569A (zh) 2005-10-12
IL140450A0 (en) 2002-02-10
MY130773A (en) 2007-07-31
AU2009200460A1 (en) 2009-02-26
IL140450A (en) 2011-11-30
HUP0004988A2 (hu) 2002-11-28
SA01210741B1 (ar) 2006-10-31
CN101081224B (zh) 2012-05-30
PL211573B1 (pl) 2012-05-31
US7820199B2 (en) 2010-10-26
ES2341751T3 (es) 2010-06-28
KR101234940B1 (ko) 2013-02-19
JP2001172174A (ja) 2001-06-26
EP1112738B1 (en) 2010-04-07
CZ302860B6 (cs) 2011-12-21
CA2329217A1 (en) 2001-06-20
SK19672000A3 (sk) 2001-09-11
RU2303440C2 (ru) 2007-07-27
AU7244300A (en) 2001-06-21
EP1112738A3 (en) 2001-07-18
EP2196195A2 (en) 2010-06-16
AU2005203771A1 (en) 2005-09-15
ECSP003836A (es) 2002-02-25
WO2001045668A3 (en) 2001-12-13
PE20010982A1 (es) 2001-09-28
TR200003787A3 (tr) 2001-07-23
RU2423106C9 (ru) 2012-06-27
WO2001045668A2 (en) 2001-06-28
ID28675A (id) 2001-06-21
CA2329217C (en) 2006-10-31
HK1034453A1 (en) 2001-10-26
RU2007104095A (ru) 2008-08-10
TR200003787A2 (tr) 2001-07-23
HUP0004988A3 (en) 2008-04-28
AU781924B2 (en) 2005-06-23
ATE463240T1 (de) 2010-04-15
DK1112738T3 (da) 2010-06-28
EG23759A (en) 2007-08-08
AR027033A1 (es) 2003-03-12
KR20110028326A (ko) 2011-03-17
EP2196195A3 (en) 2012-02-29
KR20010062542A (ko) 2001-07-07
CZ20004812A3 (cs) 2001-08-15
SK287684B6 (sk) 2011-06-06
CN1301534A (zh) 2001-07-04
PL344715A1 (en) 2001-07-02
SG109438A1 (en) 2005-03-30
CO5251435A1 (es) 2003-02-28
PT1112738E (pt) 2010-06-04
HU0004988D0 (pt) 2001-02-28
US20030086971A1 (en) 2003-05-08
US6979463B2 (en) 2005-12-27
CN101081224A (zh) 2007-12-05
KR100936572B1 (ko) 2010-01-13
NZ509028A (en) 2002-12-20

Similar Documents

Publication Publication Date Title
BR0006403A (pt) Composição de dosagem oral de liberação prolongada estável
NO951527D0 (no) Stabilt, oralt doseringspreparat med forlenget frigivelse
PT1446119E (pt) Substancias que contem ipratropio e xilometazolina na sua composicao para o tratamento da constipacao comum
CY1106430T1 (el) Φαρμακα για εισπνοη που πepιλαμβανουν βηταμιμητικα και αντιχολινepγικο
BR0000003A (pt) Azalidas e métodos de preparação das mesmas
BR0012082A (pt) Formulação farmacêutica para administração compreendendo morfina e seu uso
BR9909138A (pt) Combinação para o tratamento de dependência de álcool e drogas contendo um antagonista de opióide e um modulador de complexo receptor de nmda
BR9916860A (pt) Método de reduzir colesterol do sangue e/outriglicerìdios do sangue em um indivìduo mamìfero,preparação em forma de unidade de dosagem, e,conjunto para administrar oralmente a mesma
BR0014946A (pt) Uso de dipiridamol ou mopidamol na fabricação de um medicamento para o tratamento e prevenção de distúrbios da microcirculação dependentes da fibrina
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
BR0107721A (pt) Combinação, uso de mirtapazina e gepirona, método para o tratamento de depressão ou de um distúrbio relacionado em um indivìduo de uma espécie vertebrada, e, kit de paciente que contém meios para a administração de doses unitárias dosadas
BR0207866A (pt) Uso de flumazenil na preparação de um medicamento para o tratamento da dependência de cocaìna
AR027937A1 (es) Tratamiento de condiciones alergicas e inflamatorias
BRPI0408500A (pt) tratamento do diabetes do tipo 1 com inibidores de pde5
BR0108261A (pt) Uso de mirtazapina, método de tratamento de um distúrbio do sono em um indivìduo, e, kit para paciente para o tratamento de distúrbios do sono
Lee et al. Tepoxalin enhances the activity of an antioxidant, pyrrolidine dithiocarbamate, in attenuating tumor necrosis factor α-induced apoptosis in WEHI 164 cells
BR0009704A (pt) Utilização do osanetant para a preparação de medicamentos úteis no tratamento das perturbações do humor
Forte Paracetamol: safety versus toxicity
BR9801839A (pt) Medicamento analgésico e aplicação de (+) -0-demetiltramadol.
BR9812466A (pt) Uso de ifn-alfa e amantadina para o tratamento da hepatite c crÈnica
BR0016654A (pt) Composto, método para o tratamento da dor, e, composição farmacêutica
BR0016469A (pt) Composição para melhorar a resposta proliferativa durante a adaptação do trato gastrointestinal e uso na sìndrome do intestino delgado
MAJ Ready-Pack
Falk Diagnostic Index Kit Available From The College
Lewis Should Heroin Be Available for Pain?-Reply

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B25G Requested change of headquarter approved

Owner name: MERCK SHARP AND DOHME CORP. (US)